Human Coagulation Factor IX Drug Registration and Marketing Authorization Application Accepted
February 5, 2026
Source: drugdu
27
February 4th - Parlin Biotechnology announced on February 4 that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., recently received the "Acceptance Notice" for the drug registration and marketing authorization of human coagulation factor IX issued by the National Medical Products Administration.
The indications for human coagulation factor IX are: to treat hemophilia B patients with congenital human coagulation factor IX deficiency or patients with low levels of human coagulation factor IX due to other reasons, it can significantly increase the level of human coagulation factor IX in their blood, thereby achieving the purpose of preventing and treating bleeding.
https://finance.eastmoney.com/a/202602043641469948.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Aligning with international standards! Aidea Pharma obtains Tanzania’s ML3 GMP certification February 5, 2026
- Shijiazhuang Pharmaceutical Group’s clopidogrel emulsion injection has received a drug registration certificate. February 5, 2026
- HX111 completes first patient dosing in Phase I clinical trial February 5, 2026
- When the 31-valent pneumococcal vaccine begins Phase 3 clinical trials February 5, 2026
- Eli Lilly invests 24.3 billion yuan more in weight-loss drugs February 5, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
